Hearing This Week Could Define Course of Affy vs. Illumina; Documents Shed Light on Evolving Case | GenomeWeb

Though Affymetrix and Illumina aren't slated to face each other in court for another six months, a special hearing scheduled to take place this week may ultimately determine who wins the companies' patent-infringement suit (see BAN 8/24/2005).

Attorneys for the two array companies are expected to meet on Thursday in the US District Court in Wilmington, Del., for a Markman hearing, a key event in patent-infringement cases in which the presiding judge gets the final say in defining the scope of the claims involved in the lawsuit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.